亚太地区G-CSF/PEG-G-CSF市场规模、趋势、增长报告2030

亚太 G-CSF/PEG-G-CSF 市场，按适应症（中性粒细胞减少症、肿瘤学、慢性和自身免疫性疾病、血液病、生长协调缺陷等）、剂量（单一和组合）、给药途径（静脉注射、皮下注射）、包装（一次性小瓶和预填充注射器）、最终用户（医院和诊所、研究和学术机构、门诊手术中心等）、分销渠道（医院药房、网上药房、零售药房等）划分 - 行业趋势和预测到 2030 年。

亚太地区 G-CSF/PEG-G-CSF 市场分析和见解

发达国家和政府对癌症预防的重视程度不断提高，并采取了有意识的举措来教育早期治疗，从而促进了亚太地区 G-CSF 生物仿制药的销售市场。Grafeel、Colstim、Neukine 和 Filcad 是已获批准的生物仿制药，而且在发展中国家也具有成本效益且易于获得，将带来显著的市场增长。中国和印度是癌症患者数量不断增加的国家，这可能会提振亚太市场。因此，与使用原始生物制剂相比，使用生物仿制药有助于降低患者的医疗保健成本，从而增加了亚太地区 G-CSF 生物仿制药销售市场的需求。由于单个生物仿制药的生物制造过程复杂，生物仿制药的成本并不像仿制药那么低。自身免疫和罕见慢性疾病的日益流行预计将推动该细分市场的增长。

Data Bridge Market Research 分析，亚太地区 G-CSF/PEG-G-CSF 市场预计到 2030 年将达到 10.4956 亿美元，预测期内复合年增长率为 6.3%。本市场报告还深入介绍了定价分析、专利分析和技术进步。

报告指标	细节
预测期	2023 至 2030 年
基准年	2022
历史岁月	2021
定量单位	收入（百万美元）、销量（单位）、定价（美元）
涵盖的领域	按适应症（中性粒细胞减少症、肿瘤学、慢性和自身免疫性疾病、血液病、生长协调性缺陷等）、剂量（单药和联合用药）、给药途径（静脉注射、皮下注射）、包装（一次性使用小瓶和预填充注射器）、最终用户（医院和诊所、研究和学术机构、门诊手术中心等）、分销渠道（医院药房、网上药房、零售药房等）
覆盖国家	中国、日本、印度、澳大利亚、新西兰、印度尼西亚、泰国、越南、新加坡、菲律宾、马来西亚、亚太地区其他地区
涵盖的市场参与者	USV Private Limited、Viatris Inc.、Biocon、Fresenius Kabi AG、杭州九源基因工程有限公司、Amgen Inc.、Pfizer Inc.、Sandoz International GmbH、Apotex Inc.、Cadila Pharmaceuticals、Dr. Reddy's Laboratories Ltd.、Amneal Pharmaceuticals LLC.、Coherus BioSciences、Accord Healthcare、NAPP PHARMACEUTICALS LIMITED.、Intas Pharmaceuticals Ltd.、Mundipharma International、Teva Pharmaceutical Industries Ltd.、Spectrum Pharmaceuticals, Inc.、Kyowa Kirin Co., Ltd.、江苏恒瑞制药股份有限公司等。

亚太地区 G-CSF/ PEG-G-CSF 市场定义

粒细胞集落刺激因子 (G-CSF) 是一种用于治疗中性粒细胞减少症的药物。这是一种白细胞数量低于平均水平的疾病，是由某些形式的化疗引起的。G-CSF 的主要类型是来诺格司亭 (Granocyte)、非格司亭 (Neupogen、zarzio、nivestim、accofil)、长效 (聚乙二醇化) 非格司亭 (pegfilgrastim、neulasta、pelmeg、ziextenco) 和利培非格司亭 (lonquex)。来诺格司亭是一种糖基化重组治疗剂，其化学性质与天然存在的人类粒细胞集落刺激因子 (G-CSF) 相似或相同。各种产品包括片剂和胶囊，可治疗癌症、血液疾病、生长激素缺乏症以及慢性和自身免疫性疾病。

亚太地区 G-CSF/ PEG-G-CSF 市场动态

本节旨在了解市场驱动因素、优势、机遇、限制和挑战。下面将详细讨论所有这些内容：

驱动程序

血癌和癌症发病率不断上升

癌症是多种疾病的总称，这些疾病会影响身体的任何部位。癌症的其他术语包括恶性肿瘤和肿瘤。癌症的特征之一是异常细胞的快速形成，这些细胞生长超出正常范围，可以侵入身体的邻近部位并扩散到其他器官；后一个过程称为转移。广泛转移是癌症死亡的主要原因。

非格司亭是一种粒细胞集落刺激因子 (GCSF)，有助于增加血液中的中性粒细胞数量。非格司亭和聚乙二醇非格司亭被广泛用于在癌症化疗或放射治疗后增加白细胞。

发热性中性粒细胞减少症病例增加

发热性中性粒细胞减少症是指在严重中性粒细胞减少症期间发烧。如果患者患有中性粒细胞减少症，其感染风险可能高于平常，特定感染的严重程度也可能更高。发热性中性粒细胞减少症是癌症治疗中最常见的危及生命的并发症；其治疗通常是肿瘤急症。

发热性中性粒细胞减少症是伴有发烧的中性粒细胞减少症。中性粒细胞减少症是指血液中中性粒细胞浓度下降。中性粒细胞是一种白细胞，作为免疫系统的一部分，有助于抵抗感染。美国传染病协会将中性粒细胞减少症定义为绝对中性粒细胞计数 (ANC) 低于 1500 个细胞/立方毫米。重度中性粒细胞减少症的感染和中性粒细胞减少性发热风险急剧增加，重度中性粒细胞减少症的定义为绝对中性粒细胞计数 (ANC) 低于 500 个细胞/立方毫米。发烧定义为单次口腔温度大于或等于 101° 华氏度 (38.3° 摄氏度) 或持续体温大于或等于 100.4° 华氏度 (38.0° 摄氏度) 或更高，持续一小时或更长时间。

克制

严格的政府法规

开发非格司亭等生物仿制药的制药公司在产品审批过程中面临着重大挑战。每个国家对所有药物、治疗、疫苗和医疗器械的审批流程都不同。然而，这些审批程序很难遵循。这是因为需要各种法规和证据来证明产品的有效性和安全性。

欧洲药品管理局的监管要求确保生物仿制药与原研生物制品具有相同的高质量、安全性和有效性标准。这些要求还包括与参考产品进行严格的可比性测试，但欧盟以外的监管机构并未普遍接受这些要求。值得注意的是，如果印度批准的“类似生物制剂”、伊朗批准的“生物仿制药”、阿根廷批准的“类似生物药物”和南非批准的非原研生物制品受到欧盟批准生物仿制药所需的严格监管程序，它们可能不会获得授权。

机会

使用生物仿制药有助于降低患者的医疗成本

生物仿制药有可能从根本上改变医疗保健，为患者提供更实惠、同样有效的治疗，并为医生提供更多治疗选择。开发生物仿制药需要进行严格的分析，以证明其与参考产品的等效性，并确保其安全性、有效性和纯度没有临床意义上的差异。因此，卫生系统可以将长期节省的资金用于患者护理的整体改善。为了帮助创造一个蓬勃发展的生物仿制药市场并确保患者能够获得药物，政策制定者可以采取措施降低或消除生物仿制药的成本，并鼓励医生开出与欧洲相比更好的生物仿制药。

挑战

G-CSF 的多种副作用

粒细胞集落刺激因子 (G-CSF) 是一种用于治疗中性粒细胞减少症的药物，中性粒细胞减少症是一种疾病，某些形式的化疗会导致白细胞数量低于平均水平。G-CSF 是一种生长因子，可使骨髓产生更多的白细胞，以降低某些类型的癌症治疗后感染的风险。但是 G-CSF 有多种副作用，例如骨骼或肌肉疼痛、瘀伤、牙龈出血或流鼻血、腹泻、高烧（发烧）、呼吸困难和面色苍白、口腔、喉咙、肠道和肛门疼痛等。每 100 人中就有超过 10 人（超过 10%）会出现这些副作用。

根据 NCBI 的一项研究，大多数接受 G-CSF 的正常捐献者都会出现副作用，但程度都为轻度至中度。90% 的捐献者都经历过 G-CSF 的一些副作用。最常见的副作用是骨痛 (83%)、头痛 (39%)、身体疼痛 (23%)、疲劳 (14%) 以及恶心和呕吐 (12%)，这预计将对市场增长构成挑战。

后新冠疫情对亚太地区 G-CSF/ PEG-G-CSF 市场的影响

COVID-19 疫情对 G-CSF/PEG-G-CSF 市场产生了一定程度的积极影响。疫情实施了新的规范和法规，例如保持社交距离和封锁，以防止病毒传播。结果，世界各地的人们被迫待在家里，这导致了在家工作等新趋势的出现。这种居家生活导致疾病诊断和预后减少。人们对自我护理、锻炼和健康的关注度增加，帮助健身应用和平台在疫情后获得了显著的吸引力。

制造商正在制定各种战略决策，以在新冠疫情后实现复苏。参与者正在进行多项研发活动、产品发布和战略合作，以改进移植诊断市场所涉及的技术和测试结果。

最新动态

2018 年 7 月，Intas Pharmaceuticals Ltd. 的子公司 Accord Healthcare 在获得 CHMP（人用药品委员会）批准 Pelgraz®（培非格司亭）后，在欧洲推出了培非格司亭生物仿制药。该产品的推出帮助该公司拓展了其在欧洲的业务。
2022 年 3 月，Kashiv Biosciences 宣布其生物制品许可申请 (BLA) 已获美国食品药品监督管理局 (FDA) 批准，该药物为 filgrastim-ayow，这是一种参考 Neupogen 的生物仿制药。该产品以专有名称 RELEUKO 销售。

亚太 G-CSF/ PEG-G-CSF 市场范围

亚太地区 G-CSF/PEG-G-CSF 市场细分为适应症、剂量、给药途径、包装、最终用户和分销渠道。各细分市场之间的增长有助于您分析利基增长领域和进入市场的策略，并确定您的核心应用领域和目标市场的差异。

亚太地区 G-CSF / PEG-G-CSF 市场（按适应症划分）

中性粒细胞减少症
肿瘤学
慢性和自身免疫性疾病
血液疾病
生长激素缺乏症
其他的

根据适应症，亚太地区 G-CSF/PEG-G-CSF 进一步细分为中性粒细胞减少症、肿瘤学、慢性和自身免疫性疾病、血液病、生长激素缺乏症等。

亚太地区 G-CSF / PEG-G-CSF 市场（按剂量划分）

单核细胞增多症
组合

根据剂量，亚太地区 G-CSF/PEG-G-CSF 进一步分为单一剂量和组合剂量。

亚太地区 G-CSF / PEG-G-CSF 市场，按给药途径划分

静脉
皮下

根据给药途径，亚太地区 G-CSF/PEG-G-CSF 进一步分为静脉注射和皮下注射。

亚太地区 G-CSF / PEG-G-CSF 市场（按包装划分）

一次性使用小瓶
预充式注射器

根据包装，亚太地区的 G-CSF/PEG-G-CSF 进一步细分为一次性小瓶和预填充注射器。

亚太地区 G-CSF / PEG-G-CSF 市场，按最终用户划分

医院和诊所
研究与学术机构
门诊手术中心
其他的

根据最终用户，亚太地区 G-CSF/PEG-G-CSF 进一步细分为医院和诊所、研究和学术机构、门诊手术中心和其他。

亚太地区 G-CSF / PEG-G-CSF 市场，按分销渠道划分

医院药房
网上药店
零售药店
其他的

根据分销渠道，亚太地区 G-CSF/PEG-G-CSF 进一步细分为医院药房、网上药房、零售药房和其他。

亚太地区 G-CSF/ PEG-G-CSF 市场区域分析/见解

对亚太 G-CSF/PEG-G-CSF 市场进行分析，并根据国家、适应症、剂量、给药途径、包装、最终用户和分销渠道提供市场规模信息。

亚太 G-CSF/PEG-G-CSF 市场包括中国、日本、印度、澳大利亚、新西兰、印度尼西亚、泰国、越南、新加坡、菲律宾、马来西亚和亚太其他地区。

中国占据主导地位，因为中国是最大的消费市场，GDP 较高，拥有主要市场参与者。由于慢性病和自身免疫性疾病的患病率不断上升，预计中国市场将进一步增长。

报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。新销售、替代销售、国家人口统计、监管法案和进出口关税等数据点是用于预测单个国家市场情景的一些主要指标。此外，在对国家数据进行预测分析时，还考虑了亚太品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀少竞争而面临的挑战，以及销售渠道的影响。

竞争格局和亚太地区 G-CSF/PEG-G-CSF 市场份额分析

亚太地区 G-CSF/ PEG-G-CSF 市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、生产基地和设施、公司优势和劣势、产品发布、产品试验渠道、产品批准、专利、产品宽度和广度、应用优势、技术生命线曲线。以上提供的数据点仅与公司对亚太地区 G-CSF/ PEG-G-CSF 市场的关注有关。

在该市场开展业务的一些主要公司包括 USV Private Limited、Viatris Inc.、Biocon、Fresenius Kabi AG、杭州九源基因工程有限公司、Amgen Inc.、Pfizer Inc.、Sandoz International GmbH、Apotex Inc.、Cadila Pharmaceuticals、Dr. Reddy's Laboratories Ltd.、Amneal Pharmaceuticals LLC.、Coherus BioSciences、Accord Healthcare、NAPP PHARMACEUTICALS LIMITED.、Intas Pharmaceuticals Ltd.、Mundipharma International、Teva Pharmaceutical Industries Ltd.、Spectrum Pharmaceuticals, Inc.、Kyowa Kirin Co., Ltd.、江苏恒瑞制药股份有限公司等。

SKU-69579

Get online access to the report on the World's First Market Intelligence Cloud

Click on image to enlarge

Interactive Data Analysis Dashboard
Company Analysis Dashboard for high growth potential opportunities
Research Analyst Access for customization & queries
Competitor Analysis with Interactive dashboard
Latest News, Updates & Trend analysis
Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking

Request for Demo

表格列表

TABLE 1 BELOW ARE THE RULES AND REGULATIONS TO GET APPROVAL FOR USE IN THE MARKET:

TABLE 2 ASIA PACIFIC G-CSF/ PEG-G-CSF MARKET, BY INDICATION, 2021-2030 (USD MILLION)

TABLE 3 ASIA PACIFIC NEUTROPENIA IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 4 ASIA PACIFIC NEUTROPENIA IN G-CSF/ PEG-G-CSF MARKET, BY INDICATION, 2021-2030 (USD MILLION)

TABLE 5 ASIA PACIFIC ONCOLOGY IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 6 ASIA PACIFIC ONCOLOGY IN G-CSF/ PEG-G-CSF MARKET, BY INDICATION, 2021-2030 (USD MILLION)

TABLE 7 ASIA PACIFIC CHRONIC AND AUTO IMMUNE DISEASES IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 8 ASIA PACIFIC BLOOD DISORDERS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 9 ASIA PACIFIC GROWTH HORMONE DEFICIENCY IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 10 ASIA PACIFIC OTHERS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 11 ASIA PACIFIC G-CSF/ PEG-G-CSF MARKET, BY DOSAGE, 2020-2029 (USD MILLION)

TABLE 12 ASIA PACIFIC MONO IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 13 ASIA PACIFIC COMBINATION IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 14 ASIA PACIFIC G-CSF/ PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 15 ASIA PACIFIC SUBCUTANEOUS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 16 ASIA PACIFIC INTRAVENOUS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 17 ASIA PACIFIC G-CSF/ PEG-G-CSF MARKET, BY PACKAGING, 2020-2029 (USD MILLION)

TABLE 18 ASIA PACIFIC PRE FILLED SYRINGES IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 19 ASIA PACIFIC SINGLE USE VIALS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 20 ASIA PACIFIC G-CSF/ PEG-G-CSF MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 21 ASIA PACIFIC HOSPITALS AND CLINICS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 22 ASIA PACIFIC RESEARCH & ACADEMIC INSTITUTES IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 23 ASIA PACIFIC AMBULATORY SURGICAL CENTERS IN G-CSF/ PEG-G-CSFMARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 24 ASIA PACIFIC OTHERS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 25 ASIA PACIFIC G-CSF/ PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 26 ASIA PACIFIC HOSPITALS PHARMACY IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 27 ASIA PACIFIC RETAIL PHARMACY IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 28 ASIA PACIFIC ONLINE PHARMACY IN G-CSF/ PEG-G-CSFMARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 29 ASIA PACIFIC OTHERS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 30 ASIA-PACIFIC G-CSF / PEG-G-CSF MARKET, 2020-2030 (USD MILLION)

TABLE 31 ASIA-PACIFIC G-CSF / PEG-G-CSF MARKET, 2020-2030 (USD MILLION)

TABLE 32 ASIA-PACIFIC G-CSF / PEG-G-CSF MARKET, BY COUNTRY, 2020-2030 (USD MILLION)

TABLE 33 ASIA-PACIFIC G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)

TABLE 34 ASIA-PACIFIC NEUTROPENIA IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)

TABLE 35 ASIA-PACIFIC ONCOLOGY IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)

TABLE 36 ASIA-PACIFIC G-CSF / PEG-G-CSF MARKET, BY DOSAGE, 2020-2030 (USD MILLION)

TABLE 37 ASIA-PACIFIC G-CSF / PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 (USD MILLION)

TABLE 38 ASIA-PACIFIC G-CSF / PEG-G-CSF MARKET, BY PACKAGING, 2020-2030 (USD MILLION)

TABLE 39 ASIA-PACIFIC G-CSF / PEG-G-CSF MARKET, BY END USER, 2020-2030 (USD MILLION)

TABLE 40 ASIA-PACIFIC G-CSF / PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 (USD MILLION)

TABLE 41 CHINA G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)

TABLE 42 CHINA NEUTROPENIA IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)

TABLE 43 CHINA ONCOLOGY IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)

TABLE 44 CHINA G-CSF / PEG-G-CSF MARKET, BY DOSAGE, 2020-2030 (USD MILLION)

TABLE 45 CHINA MONO IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 46 CHINA G-CSF / PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 (USD MILLION)

TABLE 47 CHINA SUBCUTANEOUS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 48 CHINA PRE FILLED SYRINGES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 49 CHINA G-CSF / PEG-G-CSF MARKET, BY END USER, 2020-2030 (USD MILLION)

TABLE 50 CHINA HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 51 CHINA HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 52 CHINA RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 53 CHINA RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 54 CHINA RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 55 CHINA AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 56 CHINA AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 57 CHINA AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 58 CHINA G-CSF / PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 (USD MILLION)

TABLE 59 CHINA HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 60 CHINA HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 61 CHINA HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 62 CHINA RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 63 CHINA RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 64 CHINA RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 65 CHINA ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 66 CHINA ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 67 CHINA ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 68 INDIA G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)

TABLE 69 INDIA NEUTROPENIA IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)

TABLE 70 INDIA ONCOLOGY IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)

TABLE 71 INDIA G-CSF / PEG-G-CSF MARKET, BY DOSAGE, 2020-2030 (USD MILLION)

TABLE 72 INDIA MONO IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 73 INDIA COMBINATION IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 74 INDIA G-CSF / PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 (USD MILLION)

TABLE 75 INDIA SUBCUTANEOUS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 76 INDIA G-CSF / PEG-G-CSF MARKET, BY PACKAGING, 2020-2030 (USD MILLION)

TABLE 77 INDIA PRE FILLED SYRINGES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 78 INDIA G-CSF / PEG-G-CSF MARKET, BY END USER, 2020-2030 (USD MILLION)

TABLE 79 INDIA HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 80 INDIA HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 81 INDIA HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 82 INDIA RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 83 INDIA RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 84 INDIA RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 85 INDIA AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 86 INDIA AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 87 INDIA AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 88 INDIA G-CSF / PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 (USD MILLION)

TABLE 89 INDIA HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 90 INDIA HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 91 INDIA HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 92 INDIA RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 93 INDIA RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 94 INDIA RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 95 INDIA ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 96 INDIA ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 97 INDIA ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 98 INDONESIA G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)

TABLE 99 INDONESIA NEUTROPENIA IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)

TABLE 100 INDONESIA ONCOLOGY IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)

TABLE 101 INDONESIA G-CSF / PEG-G-CSF MARKET, BY DOSAGE, 2020-2030 (USD MILLION)

TABLE 102 INDONESIA MONO IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 103 INDONESIA G-CSF / PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 (USD MILLION)

TABLE 104 INDONESIA SUBCUTANEOUS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 105 INDONESIA INTRAVENOUS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 106 INDONESIA G-CSF / PEG-G-CSF MARKET, BY PACKAGING, 2020-2030 (USD MILLION)

TABLE 107 INDONESIA PRE FILLED SYRINGES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 108 INDONESIA SINGLE USE VIALS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 109 INDONESIA G-CSF / PEG-G-CSF MARKET, BY END USER, 2020-2030 (USD MILLION)

TABLE 110 INDONESIA HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 111 INDONESIA HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 112 INDONESIA HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 113 INDONESIA RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 114 INDONESIA RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 115 INDONESIA RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 116 INDONESIA AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 117 INDONESIA AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 118 INDONESIA AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 119 INDONESIA G-CSF / PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 (USD MILLION)

TABLE 120 INDONESIA HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 121 INDONESIA HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 122 INDONESIA HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 123 INDONESIA RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 124 INDONESIA RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 125 INDONESIA RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 126 INDONESIA ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 127 INDONESIA ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 128 INDONESIA ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 129 THAILAND G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)

TABLE 130 THAILAND NEUTROPENIA IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)

TABLE 131 THAILAND ONCOLOGY IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)

TABLE 132 THAILAND G-CSF / PEG-G-CSF MARKET, BY DOSAGE, 2020-2030 (USD MILLION)

TABLE 133 THAILAND MONO IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 134 THAILAND G-CSF / PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 (USD MILLION)

TABLE 135 THAILAND SUBCUTANEOUS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 136 THAILAND G-CSF / PEG-G-CSF MARKET, BY PACKAGING, 2020-2030 (USD MILLION)

TABLE 137 THAILAND PRE FILLED SYRINGES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 138 THAILAND G-CSF / PEG-G-CSF MARKET, BY END USER, 2020-2030 (USD MILLION)

TABLE 139 THAILAND HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 140 THAILAND HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 141 THAILAND HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 142 THAILAND RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 143 THAILAND RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 144 THAILAND RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 145 THAILAND AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 146 THAILAND AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 147 THAILAND AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 148 THAILAND G-CSF / PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 (USD MILLION)

TABLE 149 THAILAND HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 150 THAILAND HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 151 THAILAND HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 152 THAILAND RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 153 THAILAND RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 154 THAILAND RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 155 THAILAND ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 156 THAILAND ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 157 THAILAND ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 158 VIETNAM G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)

TABLE 159 VIETNAM NEUTROPENIA IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)

TABLE 160 VIETNAM ONCOLOGY IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)

TABLE 161 VIETNAM G-CSF / PEG-G-CSF MARKET, BY DOSAGE, 2020-2030 (USD MILLION)

TABLE 162 VIETNAM MONO IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 163 VIETNAM G-CSF / PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 (USD MILLION)

TABLE 164 VIETNAM SUBCUTANEOUS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 165 VIETNAM G-CSF / PEG-G-CSF MARKET, BY PACKAGING, 2020-2030 (USD MILLION)

TABLE 166 VIETNAM PRE FILLED SYRINGES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 167 VIETNAM G-CSF / PEG-G-CSF MARKET, BY END USER, 2020-2030 (USD MILLION)

TABLE 168 VIETNAM HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 169 VIETNAM HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 170 VIETNAM HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 171 VIETNAM RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 172 VIETNAM RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 173 VIETNAM RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 174 VIETNAM AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 175 VIETNAM AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 176 VIETNAM AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 177 VIETNAM G-CSF / PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 (USD MILLION)

TABLE 178 VIETNAM HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 179 VIETNAM HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 180 VIETNAM HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 181 VIETNAM RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 182 VIETNAM RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 183 VIETNAM RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 184 VIETNAM ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 185 VIETNAM ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 186 VIETNAM ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 187 SINGAPORE G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)

TABLE 188 SINGAPORE NEUTROPENIA IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)

TABLE 189 SINGAPORE ONCOLOGY IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)

TABLE 190 SINGAPORE G-CSF / PEG-G-CSF MARKET, BY DOSAGE, 2020-2030 (USD MILLION)

TABLE 191 SINGAPORE MONO IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 192 SINGAPORE G-CSF / PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 (USD MILLION)

TABLE 193 SINGAPORE SUBCUTANEOUS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 194 SINGAPORE INTRAVENOUS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 195 SINGAPORE G-CSF / PEG-G-CSF MARKET, BY PACKAGING, 2020-2030 (USD MILLION)

TABLE 196 SINGAPORE PRE FILLED SYRINGES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 197 SINGAPORE SINGLE USE VIALS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 198 SINGAPORE G-CSF / PEG-G-CSF MARKET, BY END USER, 2020-2030 (USD MILLION)

TABLE 199 SINGAPORE HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 200 SINGAPORE HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 201 SINGAPORE HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 202 SINGAPORE RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 203 SINGAPORE RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 204 SINGAPORE RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 205 SINGAPORE AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 206 SINGAPORE AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 207 SINGAPORE AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 208 SINGAPORE G-CSF / PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 (USD MILLION)

TABLE 209 SINGAPORE HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 210 SINGAPORE HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 211 SINGAPORE HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 212 SINGAPORE RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 213 SINGAPORE RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 214 SINGAPORE RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 215 SINGAPORE ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 216 SINGAPORE ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 217 SINGAPORE ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 218 PHILIPPINES G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)

TABLE 219 PHILIPPINES NEUTROPENIA IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)

TABLE 220 PHILIPPINES ONCOLOGY IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)

TABLE 221 PHILIPPINES G-CSF / PEG-G-CSF MARKET, BY DOSAGE, 2020-2030 (USD MILLION)

TABLE 222 PHILIPPINES MONO IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 223 PHILIPPINES G-CSF / PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 (USD MILLION)

TABLE 224 PHILIPPINES SUBCUTANEOUS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 225 PHILIPPINES G-CSF / PEG-G-CSF MARKET, BY PACKAGING, 2020-2030 (USD MILLION)

TABLE 226 PHILIPPINES PRE FILLED SYRINGES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 227 PHILIPPINES G-CSF / PEG-G-CSF MARKET, BY END USER, 2020-2030 (USD MILLION)

TABLE 228 PHILIPPINES HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 229 PHILIPPINES HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 230 PHILIPPINES HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 231 PHILIPPINES RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 232 PHILIPPINES RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 233 PHILIPPINES RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 234 PHILIPPINES AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 235 PHILIPPINES AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 236 PHILIPPINES AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 237 PHILIPPINES G-CSF / PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 (USD MILLION)

TABLE 238 PHILIPPINES HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 239 PHILIPPINES HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 240 PHILIPPINES HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 241 PHILIPPINES RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 242 PHILIPPINES RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 243 PHILIPPINES RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 244 PHILIPPINES ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 245 PHILIPPINES ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 246 PHILIPPINES ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 247 MALAYSIA G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)

TABLE 248 MALAYSIA NEUTROPENIA IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)

TABLE 249 MALAYSIA ONCOLOGY IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)

TABLE 250 MALAYSIA G-CSF / PEG-G-CSF MARKET, BY DOSAGE, 2020-2030 (USD MILLION)

TABLE 251 MALAYSIA MONO IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 252 MALAYSIA G-CSF / PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 (USD MILLION)

TABLE 253 MALAYSIA SUBCUTANEOUS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 254 MALAYSIA G-CSF / PEG-G-CSF MARKET, BY PACKAGING, 2020-2030 (USD MILLION)

TABLE 255 MALAYSIA PRE FILLED SYRINGES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 256 MALAYSIA G-CSF / PEG-G-CSF MARKET, BY END USER, 2020-2030 (USD MILLION)

TABLE 257 MALAYSIA HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 258 MALAYSIA HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 259 MALAYSIA HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 260 MALAYSIA RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 261 MALAYSIA RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 262 MALAYSIA RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 263 MALAYSIA AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 264 MALAYSIA AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 265 MALAYSIA AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 266 MALAYSIA G-CSF / PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 (USD MILLION)

TABLE 267 MALAYSIA HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 268 MALAYSIA HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 269 MALAYSIA HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 270 MALAYSIA RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 271 MALAYSIA RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 272 MALAYSIA RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 273 MALAYSIA ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 274 MALAYSIA ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 275 MALAYSIA ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

图片列表

FIGURE 1 ASIA PACIFIC G-CSF / PEG-G-CSF MARKET: SEGMENTATION

FIGURE 2 ASIA PACIFIC G-CSF / PEG-G-CSF MARKET: DATA TRIANGULATION

FIGURE 3 ASIA PACIFIC G-CSF / PEG-G-CSF MARKET: DROC ANALYSIS

FIGURE 4 ASIA PACIFIC G-CSF / PEG-G-CSF MARKET: ASIA PACIFIC VS REGIONAL MARKET ANALYSIS

FIGURE 5 ASIA PACIFIC G-CSF / PEG-G-CSF MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 ASIA PACIFIC G-CSF / PEG-G-CSF MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 ASIA PACIFIC G-CSF / PEG-G-CSF MARKET: DBMR MARKET POSITION GRID

FIGURE 8 ASIA PACIFIC G-CSF / PEG-G-CSF MARKET: MARKET END USER COVERAGE GRID

FIGURE 9 ASIA PACIFIC G-CSF / PEG-G-CSF MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 ASIA PACIFIC G-CSF / PEG-G-CSF MARKET: SEGMENTATION

FIGURE 11 THE INCREASE IN CANCER PROPHYLAXIS IN DEVELOPED COUNTRIES AND INITIATIVES TAKEN BY GOVERNMENTS ARE TO DRIVE THE ASIA PACIFIC G-CSF / PEG-G-CSF MARKET FROM 2023 TO 2030

FIGURE 12 NEUTROPENIA SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC G-CSF / PEG-G-CSF MARKET IN 2023 & 2030

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE ASIA PACIFIC G-CSF / PEG-G-CSF MARKET

FIGURE 14 ASIA PACIFIC G-CSF/ PEG-G-CSF MARKET: BY INDICATION CATEGORY, 2022

FIGURE 15 ASIA PACIFIC G-CSF/ PEG-G-CSF MARKET: BY INDICATION CATEGORY, 2021-2030 (USD MILLION)

FIGURE 16 ASIA PACIFIC G-CSF/ PEG-G-CSF MARKET: BY INDICATION CATEGORY, CAGR (2022-2029)

FIGURE 17 ASIA PACIFIC G-CSF/ PEG-G-CSF MARKET: BY INDICATION CATEGORY, LIFELINE CURVE

FIGURE 18 ASIA PACIFIC G-CSF/ PEG-G-CSF MARKET: BY DOSAGE, 2022

FIGURE 19 ASIA PACIFIC G-CSF/ PEG-G-CSF MARKET: BY DOSAGE, 2021-2030 (USD MILLION)

FIGURE 20 ASIA PACIFIC G-CSF/ PEG-G-CSF MARKET: BY DOSAGE, CAGR (2023-2030)

FIGURE 21 ASIA PACIFIC G-CSF/ PEG-G-CSF MARKET: BY DOSAGE, LIFELINE CURVE

FIGURE 22 ASIA PACIFIC G-CSF/ PEG-G-CSF MARKET: BY ROUTE OF ADMINISTRATION, 2022

FIGURE 23 ASIA PACIFIC G-CSF/ PEG-G-CSF MARKET: BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

FIGURE 24 ASIA PACIFIC G-CSF/ PEG-G-CSF MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2023-2030)

FIGURE 25 ASIA PACIFIC G-CSF/ PEG-G-CSF MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 26 ASIA PACIFIC G-CSF/ PEG-G-CSF MARKET: BY PACKAGING, 2022

FIGURE 27 ASIA PACIFIC G-CSF/ PEG-G-CSF MARKET: BY PACKAGING, 2021-2030 (USD MILLION)

FIGURE 28 ASIA PACIFIC G-CSF/ PEG-G-CSF MARKET: BY PACKAGING, CAGR (2023-2030)

FIGURE 29 ASIA PACIFIC G-CSF/ PEG-G-CSF MARKET: BY PACKAGING, LIFELINE CURVE

FIGURE 30 ASIA PACIFIC G-CSF/ PEG-G-CSF MARKET: BY END USER, 2022

FIGURE 31 ASIA PACIFIC G-CSF/ PEG-G-CSF MARKET: BY END USER, 2021-2030 (USD MILLION)

FIGURE 32 ASIA PACIFIC G-CSF/ PEG-G-CSF MARKET: BY END USER, CAGR (2023-2030)

FIGURE 33 ASIA PACIFIC G-CSF/ PEG-G-CSF MARKET: BY END USER, LIFELINE CURVE

FIGURE 34 ASIA PACIFIC G-CSF/ PEG-G-CSF MARKET: BY DISTRIBUTION CHANNEL, 2022

FIGURE 35 ASIA PACIFIC G-CSF/ PEG-G-CSF MARKET: BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

FIGURE 36 ASIA PACIFIC G-CSF/ PEG-G-CSF MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)

FIGURE 37 ASIA PACIFIC G-CSF/ PEG-G-CSF MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 38 ASIA-PACIFIC G-CSF/PEG-G-CSF MARKET: SNAPSHOT (2022)

FIGURE 39 ASIA-PACIFIC G-CSF/PEG-G-CSF MARKET: BY COUNTRY (2022)

FIGURE 40 ASIA-PACIFIC G-CSF/PEG-G-CSF MARKET: BY COUNTRY (2022 & 2030)

FIGURE 41 ASIA-PACIFIC G-CSF/PEG-G-CSF MARKET: BY COUNTRY (2022 & 2030)

FIGURE 42 ASIA-PACIFIC G-CSF/PEG-G-CSF MARKET: BY INDICATION (2023-2030)

FIGURE 43 ASIA PACIFIC G-CSF / PEG-G-CSF MARKET: COMPANY SHARE 2022 (%)

查看详细信息

研究方法

数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。该阶段包括通过各种来源和策略获取市场信息或相关数据。它包括提前检查和规划从过去获得的所有数据。它同样包括检查不同信息源中出现的信息不一致。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。要了解更多信息，请请求分析师致电或下拉您的询问。

DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析和主要（行业专家）验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、专利分析、定价分析、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息，请向我们的行业专家咨询。

可定制

Data Bridge Market Research 是高级形成性研究领域的领导者。我们为向现有和新客户提供符合其目标的数据和分析而感到自豪。报告可定制，包括目标品牌的价格趋势分析、了解其他国家的市场（索取国家列表）、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表（事实手册）中的数据，或者可以帮助您根据报告中的数据集创建演示文稿。

亚太地区 G-CSF/PEG-G-CSF 市场 – 行业趋势和 2030 年预测

通过敏捷供应链咨询解决关税挑战

亚太地区 G-CSF/PEG-G-CSF 市场分析和见解

亚太地区 G-CSF/ PEG-G-CSF 市场定义

亚太地区 G-CSF/ PEG-G-CSF 市场动态

后新冠疫情对亚太地区 G-CSF/ PEG-G-CSF 市场的影响

亚太 G-CSF/ PEG-G-CSF 市场范围

亚太地区 G-CSF/ PEG-G-CSF 市场区域分析/见解

竞争格局和亚太地区 G-CSF/PEG-G-CSF 市场份额分析

Get online access to the report on the World's First Market Intelligence Cloud

目录

表格列表

图片列表

研究方法

可定制

报告

市场洞察

支持

解决方案

亚太地区 G-CSF/PEG-G-CSF 市场 – 行业趋势和 2030 年预测

通过敏捷供应链咨询解决关税挑战

亚太地区 G-CSF/PEG-G-CSF 市场分析和见解

亚太地区 G-CSF/ PEG-G-CSF 市场定义

亚太地区 G-CSF/ PEG-G-CSF 市场动态

后新冠疫情对亚太地区 G-CSF/ PEG-G-CSF 市场的影响

亚太 G-CSF/ PEG-G-CSF 市场范围

亚太地区 G-CSF/ PEG-G-CSF 市场区域分析/见解

竞争格局和亚太地区 G-CSF/PEG-G-CSF 市场份额分析

Get online access to the report on the World's First Market Intelligence Cloud

目录

表格列表

图片列表

研究方法

可定制

浏览相关页面